Click the button below to contact us or submit your feedback about this product.
ImmunoArrayᵀᴹ Paraneoplastic Neurological Syndrome (PNS) & Autoimmune Encephalitis (AE) Associated Autoantibody Detection Service/Antigen Microarray (CAT#: NA-0726-FY6)
Paraneoplastic Neurological Syndrome (PNS) & Autoimmune Encephalitis (AE) Associated Autoantibody Detection Service is an ultra-sensitive, high-throughput multiplexed antigen microarray platform tailored for cutting-edge neuro-immunology and neuro-oncology research. By immobilizing 34 carefully vetted neurological autoantigens in their native three-dimensional configurations on an advanced 3D microchip matrix, the platform maps complex autoantibody fingerprints across a wide 1-65000 dynamic range. Capable of simultaneous dual-isotype detection (IgG/IgM/IgA) across 16 parallel clinical samples per slide, this service requires a mere 5 μL sample volume, offering deep multi-parameter profiling at less than 1/10 the cost of conventional ELISAs. Equipped with internal Ig/anti-Ig pairs for optimal data normalization, it serves as an indispensable discovery engine for mapping pathogenic surface antibodies, establishing multi-marker signatures for hidden tumors, and guiding clinical immunotherapy strategies.
| Specifications | |
|---|---|
| Size | Standard microchip substrate layout (Standard glass slide format) |
| Throughput Level | High-throughput multi-sample parallel screening; 16 samples can be processed simultaneously per individual slide |
| Protein Count | Features 34 highly specific neurological autoantigens (meticulously selected via a comprehensive review of peer-reviewed literature) |
| Proteome Coverage | Target-specific disease coverage (Capable of multiplexed profiling of over 120 autoantibodies per reaction well) |
| Full-Length Protein Ratio | High conformational fidelity (Pure antigens are coated onto a 3D matrix to optimally preserve their native three-dimensional structures) |
| Expression System | Specialized eukaryotic and purified expression pipelines engineered to maintain intact biological epitopes |
| Purification Method | Advanced affinity and high-purity antigen isolation |
| Arraying Technology | Precise automated deposition onto a proprietary three-dimensional (3D) microchip surface |
| Quality Control | Integrated internal Ig and anti-Ig control pairs within every array for rigorous data normalization and absolute quantification |
| Features | High Multiplexing & Micro-Volume Screening: Drastically improves upon conventional single-plex ELISA formats by assessing more than 120 distinct autoantibodies in parallel within a single reaction well, from an ultra-low sample volume of just 5 μL of serum or alternative biofluids. Dual-Isotype Fluorescence Interrogation: Employs advanced dual-color fluorophore-conjugated secondary antibodies to independently read two distinct antibody classes (such as IgG/IgM or IgA) on the exact same array surface, preserving rare or limited clinical samples. Vast Analytical Dynamic Range: Provides superior signal detection capabilities ranging from 1 to 65000 Relative Fluorescence Units (RFU), supporting highly precise relative quantification and semi-quantitative profiling through standard curves. Unparalleled Versatility & Cost Efficiency: Features a highly flexible setup by immobilizing diverse target biomolecules (proteins, peptides, nucleic acids) to screen across multiple antibody subtypes, reducing operational overhead to less than 1/10 the cost of traditional ELISA kits. |
| Application Fields | Differential Diagnostics (PNS vs. AE): Assisting clinicians and researchers in distinguishing between Paraneoplastic Neurological Syndromes (PNS) and broader Autoimmune Encephalitis (AE) variants based on comprehensive clinical signs, MRI findings, and CSF data. Oncology Pre-Screening & Cancer Flagging: Mapping "high-risk" intracellular classic antibodies-including Anti-Hu, Anti-Ri, Anti-CRMP5, Anti-amphiphysin, Anti-Ma1, and Anti-Ma2-which serve as critical, early-warning biomarkers for underlying, occult malignancies. Pathogenic Surface Antibody Profiling: Identifying cell-surface targeting autoantibodies-such as Anti-NMDA, Anti-AMPA, Anti-LGI1, and Anti-CASPR2-which directly drive neuronal damage and correlate with highly favorable responses to early immunotherapies. Autoimmune Neuropathy & Neuro-Disorder Research: Mapping dense autoantibody cross-talk driving systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), mixed connective tissue disorders, and post-viral neuro-immunological monitoring (e.g., SARS-CoV-2, influenza, RSV). Therapeutic Stratification & Trial Monitoring: Providing highly reliable multi-parameter models to guide targeted treatment choices (cancer control for PNS vs. direct immunosuppression for AE), analyze drug efficacy, and monitor toxicities during clinical trials. |
DatasheetFor Research Use Only | Not For Clinical Use
Related products
- ImmunoArrayᵀᴹ Cancer and Tumor-Related Autoantibody Detection Service (CAT#: NA-0726-FY16)
- ImmunoArrayᵀᴹ Autoantibody Detection Microarray Service (CAT#: NA-0726-FY12)
- ImmunoArrayᵀᴹ Systemic Autoimmune Disease-Related Autoantibody Detection Service (CAT#: NA-0726-FY27)
- ImmunoArrayᵀᴹ Extractable Nuclear Antigen (ENA) and Antinuclear Antibody (ANA) Detection Service (32 Antigens) (CAT#: NA-0726-FY25)
- ImmunoArrayᵀᴹ Neuroimmune-Related Autoantibody Detection Service (CAT#: NA-0726-FY15)
- ImmunoArrayᵀᴹ Glycosphingolipid (GSL) Glycan Microarray (CAT#: NA-0726-FY36)
- ImmunoArrayᵀᴹ Antiphospholipid Syndrome (APS) and Neutrophil Extracellular Traps (NETs) Related Native Protein Autoantibody Detection Service (CAT#: NA-0726-FY17)
- ImmunoArrayᵀᴹ Myasthenia Gravis-Related Autoantibody Detection Microarray Service (68-Antigen Array) (CAT#: NA-0726-FY14)
Services:
Resource:
Applications:
Online Inquiry